Mounjaro in India

What is Mounjaro?

Mounjaro is the brand name for tirzepatide, an injectable medication from Eli Lilly. It belongs to a newer class of medicines that act on two natural gut hormone pathways — GLP-1 and GIP — which help the body regulate blood sugar and appetite.

In India, Mounjaro is prescribed for two main reasons:

• Type 2 diabetes, to help improve blood sugar control in adults whose diabetes is not adequately managed by other medicines such as metformin alone.
• Chronic weight management in adults living with obesity, or with overweight plus a weight-related health condition such as high blood pressure, sleep apnoea, or dyslipidaemia.

Mounjaro is given as a once-weekly injection using a pre-filled pen, usually into the skin of the abdomen, thigh, or upper arm. It is not a tablet, and it is not insulin. Many patients in India are prescribed it alongside lifestyle changes — diet, physical activity, and sometimes existing diabetes medicines like metformin — rather than as a standalone solution.

It is typically considered for adults whose doctor has assessed their HbA1c, BMI, and overall risk profile. It is not appropriate for everyone — for example, people with a personal or family history of certain thyroid cancers, or with a history of pancreatitis, may be advised against it.

Mounjaro is a prescription-only medicine in India and should be obtained through a licensed pharmacist with a valid prescription.

Always consult your doctor before starting or changing any GLP-1 medication.

Who makes Mounjaro?

Mounjaro is manufactured and marketed by Eli Lilly, a global pharmaceutical company. Mounjaro is the originator brand for the molecule tirzepatide — meaning Eli Lilly developed the molecule and Mounjaro is not a generic version of anyone else's product.

In India, Mounjaro has been approved by the Central Drugs Standard Control Organisation (CDSCO) for use in adults, and is distributed through Eli Lilly's authorised channels and licensed Indian pharmacists. As with any prescription medicine, availability at a specific pharmacist can vary by city and stock.

Prices vary across Indian pharmacies — see the price comparator within Glipin for current listings rather than relying on a single number. Glipin is not affiliated with Eli Lilly and does not endorse or receive any commission from the manufacturer.

Always consult your doctor before starting or changing any GLP-1 medication.

Typical dose schedule

Mounjaro is taken as one injection per week, on the same day each week, at any time of day, with or without food. Doctors almost always start patients on a low dose and increase it gradually — this is called titration, and it helps the body adjust and reduces side effects like nausea.

The typical pattern looks like this:

• Starting dose: 2.5 mg once weekly for the first 4 weeks. This dose is for the body to get used to the medicine and is not usually expected to produce the full effect.
• First step-up: 5 mg once weekly for at least the next 4 weeks.
• Further step-ups: If the doctor decides more effect is needed and side effects are tolerable, the dose may be increased in 2.5 mg steps (to 7.5 mg, 10 mg, 12.5 mg, and up to 15 mg), with at least 4 weeks between each increase.
• Maintenance: Most patients settle on a dose somewhere between 5 mg and 15 mg weekly, depending on their response.

Some people stay on a lower dose if it is working well; others need to go higher. Doctors individualise this based on blood sugar readings, weight changes, and how the patient is tolerating the medicine.

Your prescribing doctor will set your exact dose based on your response and any side effects.

Common side effects

Most side effects of tirzepatide are related to the digestive system and tend to be strongest in the first few weeks after starting or after a dose increase. For many people they ease over time as the body adjusts.

Commonly reported experiences include:

• Nausea — often described as a queasy feeling, especially after larger or richer meals.
• Reduced appetite and feeling full sooner than usual. Many people simply eat smaller portions.
• Diarrhoea or, conversely, constipation.
• Vomiting, more common during early weeks or after a step-up in dose.
• Indigestion, burping, bloating, or stomach discomfort.
• Tiredness in the first few weeks.
• Mild injection-site reactions such as redness or itching at the spot of injection.

For people also taking diabetes medicines such as sulphonylureas or insulin alongside Mounjaro, low blood sugar (hypoglycaemia) can occur — this is something doctors usually watch for and may adjust other medicines to prevent.

Most of these effects are mild to moderate and self-limiting. However, some symptoms are more serious.

Contact your doctor immediately if you experience severe or persistent abdominal pain (especially pain that radiates to the back, which can be a sign of pancreatitis), persistent vomiting or signs of dehydration, signs of an allergic reaction such as swelling of the face, lips, or throat, difficulty breathing, severe rash, yellowing of the skin or eyes, a lump or swelling in the neck, vision changes, or symptoms of very low blood sugar such as shakiness, sweating, confusion, or fainting. Do not stop or change your dose without medical advice.